March 3, 2026Open Access

Targeting the NEK7 / NLRP3 Inflammasome Axis: Synergistic Protection of Intravitreal MCC950 and Systemic Metformin Against Diabetic Retinopathy in Rats

Key Points

The combination of MCC950 and metformin significantly reduces diabetic retinopathy-related damage.
Results show decreased apoptosis and oxidative stress compared to controls, indicating effective intervention.
Observational analysis reveals that this dual therapy modulates the NEK7/NLRP3 inflammasome pathway effectively.
May enable new therapeutic strategies for diabetic retinopathy, suggesting a need for clinical trials.

Abstract

The study demonstrates that the combination of systemic metformin and intravitreal MCC950 confers superior protection against DR by synergistically inhibiting the NEK7/NLRP3 inflammasome pathway, resulting in reduced oxidative stress, apoptosis and inflammatory response. This novel combinational strategy presents a promising therapeutic approach for DR.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Kexuan Ren

Xiaofeng Li

Journals

Endocrinology Diabetes & Metabolism

SHILAP Revista de lepidopterología

Actions

Institutions

Affiliated Zhongshan Hospital of Dalian University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Targeting the NEK7 / NLRP3 Inflammasome Axis: Synergistic Protection of Intravitreal MCC950 and Systemic Metformin Against Diabetic Retinopathy in Rats

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider